Abstract
Ambrex, a polyherbal formulation was tested for its antihypercholesterolemic effect against experimentally induced hypercholesterolemia in rats. Alteration in the levels of serum marker enzymes, alanine amino transferase (ALT), aspartate amino transferase (AST), lactate dehydrogenase (LDH), alkaline phosphatase (ALP) and general biochemical parameters glucose, protein, urea and creatinine were tested in both treated and untreated groups. Rats treated with high fat diet for four weeks exhibited hypercholesterolemia. Oral administration of ambrex at a dose of 40 mg/kg body weight significantly decreased serum total cholesterol, triglycerides and low density lipoproteins (LDL) levels and there was a concomitant increase in serum high density lipoprotein (HDL) levels. Atherogenic index of the ambrex treated group showed marked improvement compared to other groups. Studies established that ambrex might be a safe drug that exhibits negligible toxic effects on liver and kidney functions under experimental condition. The histopathalogical observation of liver tissue also confirms the same. The results shows the ambrex possess considerable antihypercholesterolemic activity compared with standard drug, atorvastatin. Key words: Hypercholesterolemia, amber, Withania somnifera, atorvastatin.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
